Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post Q4 2025 Earnings of $0.42 Per Share, Zacks Research Forecasts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) – Stock analysts at Zacks Research reduced their Q4 2025 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued on Monday, May 27th. Zacks Research analyst R. Department now expects that the company will earn $0.42 per share for the quarter, down from their previous forecast of $0.45. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.12) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at $3.57 EPS.

Several other research firms have also issued reports on APLS. UBS Group reduced their price target on Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Wedbush decreased their target price on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Citigroup cut their price target on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Oppenheimer lifted their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $76.27.

Check Out Our Latest Analysis on Apellis Pharmaceuticals

Apellis Pharmaceuticals Price Performance

APLS opened at $40.56 on Wednesday. The company has a fifty day moving average price of $49.51 and a two-hundred day moving average price of $56.96. The firm has a market capitalization of $4.92 billion, a PE ratio of -11.73 and a beta of 0.97. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.02 and a current ratio of 3.77.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). The business had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The firm’s quarterly revenue was up 284.3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.56) earnings per share.

Insider Transactions at Apellis Pharmaceuticals

In other news, CFO Timothy Eugene Sullivan sold 6,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $63.22, for a total value of $379,320.00. Following the sale, the chief financial officer now owns 93,338 shares of the company’s stock, valued at $5,900,828.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CFO Timothy Eugene Sullivan sold 6,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $63.22, for a total value of $379,320.00. Following the completion of the transaction, the chief financial officer now owns 93,338 shares in the company, valued at approximately $5,900,828.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Jeffrey Delong sold 9,913 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $56.90, for a total value of $564,049.70. Following the sale, the insider now owns 54,693 shares in the company, valued at approximately $3,112,031.70. The disclosure for this sale can be found here. Insiders sold 448,012 shares of company stock valued at $26,015,139 in the last ninety days. 6.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in APLS. Vanguard Group Inc. lifted its stake in Apellis Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock valued at $572,003,000 after acquiring an additional 85,701 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Apellis Pharmaceuticals by 38.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after purchasing an additional 677,098 shares during the period. Assenagon Asset Management S.A. increased its position in Apellis Pharmaceuticals by 109.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after buying an additional 1,121,497 shares during the last quarter. Polar Capital Holdings Plc raised its stake in Apellis Pharmaceuticals by 126.6% in the third quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares during the period. Finally, Norges Bank acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $56,640,000. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Featured Stories

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.